SEC Form 4 · accession 0001055726-18-000021
INOVIO PHARMACEUTICALS, INC. · INO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Simon X Benito
Director
Period of report
Apr 12, 2018
Accepted (ET)
Apr 13, 2018 · 6:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001055726
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 12, 2018 | M | 3,750 | $3.56 | A | 31,548 | D | |
| Common StockF1 | Apr 12, 2018 | S | 3,750 | $5.2317 | D | 27,798 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock OptionsF2 | $3.56 | Apr 12, 2018 | M | 3,750 | D | May 2, 2008 | May 2, 2018 | Common Stock | 3,750 | 0 | D |
Explanation of responses
- F1This transaction was executed in multiple trades at prices ranging from $5.23 to $5.235, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- F2Given effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014.